{"text": "TITLE:\n      Scalp Cooling to Prevent Chemo-induced Hair Loss\nSUMMARY:\n      Determine that the Orbis Paxman Hair Loss Prevention System is safe and effective in\n      reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or\n      adjuvant chemotherapy.\nDETAILED DESCRIPTION:\n      Cooling the scalp during chemotherapy may help reduce the chances of losing hair during\n      treatment. The investigators are hoping that using the PAXMAN Orbis Scalp Cooling Device may\n      stop patients who are undergoing chemotherapy from losing their hair.\nELIGIBILITY CRITERIA:\n      Inclusion Criteria:\n          -  New diagnosis of breast cancer stage 1-2\n          -  Planning to undergo neoadjuvant or adjuvant chemotherapy with curative intent\n          -  Chemotherapy must be planned for at least 4 cycles of full-dose anthracycline or\n             taxane based chemotherapy regimen,\n          -  Defined as one of the following regimens: - Adriamycin 60mg/m2 with cyclophosphamide\n             600mg/m2 - Epirubicin 90-100mg/m2 with cyclophosphamide 600mg/m2 - Paclitaxel\n             80mg-90/m2 weekly (every three weeks constitute a cycle), or 175 mg/m2 every 2-3\n             weeks as a single agent - Docetaxel 100mg/m2 as a single agent - Docetaxel 75mg/m2\n             with cyclophosphamide 600mg/m2 - Docetaxel 75mg/m2 with carboplatin AUC of 6 and\n             trastuzumab at standard doses\n          -  Trastuzumab at standard doses is allowed in combination with taxane based\n             chemotherapy\n          -  Administration of chemotherapy on a dose dense schedule is allowed as clinically\n             indicated.\n        Exclusion Criteria:\n          -  Stage 3 or 4 breast cancer or any other concurrent malignancy including hematological\n             malignancies (i.e. leukemia or lymphoma)\n          -  Baseline alopecia (defined CTCAE v4.0 grade > 0, see appendix B for CTCAE v4.0 scale)\n          -  Subjects with cold agglutinin disease or cold urticaria\n          -  Subjects who are scheduled for bone marrow ablation chemotherapy\n          -  Subjects receiving chemotherapy with concurrent anthracycline and taxane (AT or TAC)\n          -  Male gender\n", "cuis": "C0002170 C0036270 C1278997 C3665472 C0012082 C1552616 C1706244 C0199176 C0002170 C0006142 C0678222 C0392920 C3665472 C0013216 C0580690 C0013218 C2717829 C0002170 C0600558 C0085533 C0281265 C0678257 C0033080 C1521941 C0392920 C3665472 C0013216 C0580690 C0013218 C2717829 C0036270 C1552861 C0018494 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0392347 C0025080 C3887560 C0027873 C0036270 C1278997 C0392920 C3665472 C0013216 C0580690 C0013218 C2717829 C0018494 C0243161 C0013893 C0243161 C2216702 C0278485 C2216694 C2216695 C0278486 C0278488 C2216701 C0278487 C2216696 C2216697 C2216698 C2216699 C2216700 C2585997 C3496355 C3843716 C0085533 C0281265 C0032074 C0600558 C0003234 C0278941 C0013216 C0392920 C3665472 C0805598 C3845185 C0392920 C0906410 C0914218 C0215136 C0010583 C1701716 C1271102 C0085752 C2945654 C0040808 C1704788 C3539106 C0010583 C1701716 C1271102 C0014582 C0071126 C0144576 C0056685 C0246415 C0087136 C0723338 C0010583 C1701716 C1271102 C0079083 C0246415 C0728747 C0038137 C2828392 C3272550 C0728747 C0215136 C3539181 C3539182 C3539954 C3539955 C3539956 C3539957 C3539959 C3539960 C3539961 C3539962 C3539963 C3539964 C3539965 C3539966 C3539967 C3539968 C3539969 C3539970 C3539971 C3539972 C3539973 C3539974 C3539975 C3539976 C3539977 C3539978 C3539979 C3540026 C3540027 C3540028 C3540030 C3540031 C3540719 C3540720 C3540721 C3540722 C3540723 C3540724 C3540740 C3854036 C3811910 C0052142 C0251244 C0965970 C0038137 C2828392 C3272550 C0392920 C3665472 C0013216 C0580690 C0013218 C2717829 C1533734 C0725057 C0376495 C3845829 C0001563 C0036589 C0455708 C1534841 C2360550 C0392920 C3665472 C0013216 C0580690 C0013218 C2717829 C0086960 C1444656 C0243161 C0006142 C0678222 C0006826 C1306459 C3842363 C0441771 C0457163 C3869916 C3869917 C0006826 C0348374 C0023418 C0024299 C0002170 C0003617 C1552860 C0348899 C0496779 C0496860 C0869813 C1269000 C3244287 C0286840 C0175659 C0349674 C0237849 C0684254 C0728774 C0175816 C1264008 C0221207 C0281342 C0392920 C3665472 C0013216 C0580690 C0013218 C2717829 C0086960 C0003234 C0278941 C0392920 C3665472 C0013216 C0580690 C0013218 C2717829 C0215136 ", "concepts": "Hair Loss, Scalps, Scalp, Chemo, Prevental summary, summary Prevention, Hair Loss Breast cancer, Breast cancer, Chemotherapy, Chemotherapy, Chemotherapy, TB chemotherapy, polychemotherapy, Polychemotherapy, alopecia, Neoadjuvant adjuvant chemotherapy, prior adjuvant chemotherapy description, prescription, prescription Chemotherapy, Chemotherapy, Chemotherapy, TB chemotherapy, polychemotherapy, Polychemotherapy, scalp, help, hair Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, hoping, Device, Devices, Devic, Scalps, Scalp Chemotherapy, Chemotherapy, Chemotherapy, TB chemotherapy, polychemotherapy, Polychemotherapy, hair criteria, Eligibility Criteria breast cancer staging, Breast cancer stage I, breast cancer stage 0, breast cancer stage I, Breast cancer stage II, Breast cancer stage IV, breast cancer stage IV, Breast cancer stage III, breast cancer stage IIa, breast cancer stage IIb, breast cancer stage IIIa, breast cancer stage IIIb, breast cancer stage IIIc, New diagnosis, 1-2, 1-2 adjuvant chemotherapy, prior adjuvant chemotherapy, Planning, Neoadjuvant Anthracyclines, anthracyclines, Chemotherapy, chemotherapy, Chemotherapy NOS, Chemotherapy Rx, IV Chemotherapy Cancer chemotherapy regimen, ICE chemotherapy regimen 5, EEPFL chemotherapy regimen, taxane CTX - cyclophosphamide, d4-cyclophosphamide, Oral cyclophosphamide, Adriamycin, regimens, regimen, Defined, Defined CTX - cyclophosphamide, d4-cyclophosphamide, Oral cyclophosphamide, Epirubicin, Tepirubicin, Paclitaxel cyclen Docetaxel, single, singlet CTX - cyclophosphamide, d4-cyclophosphamide, Oral cyclophosphamide, carboplatin, Docetaxel trastuzumab, standards, Standard, Standard Trastuzumab, taxane, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, Combination, AP combination, MP combination, ET combination, standards, Standard, Standard Chemotherapy, Chemotherapy, Chemotherapy, TB chemotherapy, polychemotherapy, Polychemotherapy Administration, Administration Set, Readministration, Administrative, Oral Administration, Self Administration, Administration type, Administration note, Administration note, Chemotherapy, Chemotherapy, Chemotherapy, TB chemotherapy, polychemotherapy, Polychemotherapy, schedule Indicated Criteria Breast cancer, Breast cancer, malignancy, Malignancy, No malignancy, Stage 3, Stage 3c, Stage 3C2, Stage 3C1 malignancies, cns malignancies, leukemia, lymphoma alopecia, Appendix, appendix, Appendix, Appendix, Appendix, Appendix, Appendix, grade, gradex, scales, scale, scales, scaler, Vaseline cold agglutinin disease, Chronic cold agglutinin disease, cold urticaria bone marrow ablation, Chemotherapy, Chemotherapy, Chemotherapy, TB chemotherapy, polychemotherapy, Polychemotherapy, schedule Anthracyclines, anthracyclines, Chemotherapy, Chemotherapy, Chemotherapy, TB chemotherapy, polychemotherapy, Polychemotherapy, taxane "}
